SCHEMBL14474192

SCHEMBL14474192

CCOc1cc(-c2ccc(F)cc2)cc2c(NC)nc(-c3ncccn3)nc12

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CHRNA7 P36544 4/20 0.43
▸ LMNA P02545 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ GRM5 P41594 3/20 0.37
▸ EGFR P00533 4/20 0.36
▸ KDM4E B2RXH2 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ CYP3A4 P08684 1/20 0.36
▸ CYP2D6 P10635 1/20 0.36
▸ HPGD P15428 1/20 0.36
▸ CYP2C19 P33261 1/20 0.36
▸ SYK P43405 1/20 0.35
▸ ERBB2 P04626 2/20 0.35
▸ S1PR1 P21453 1/20 0.35
▸ NR3C1 P04150 1/20 0.35
▸ POLB P06746 1/20 0.35
▸ SSTR5 P35346 1/20 0.35
▸ KCNH2 Q12809 1/20 0.35
▸ KIT P10721 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16185167 0.92 GRM5 (0.38) CHRNA7LMNAMAPTGRM5EGFR
SCHEMBL16185138 0.90 GRM5 (0.48) CHRNA7LMNAMAPTGRM5EGFR
SCHEMBL14474198 0.89 S1PR1 (0.46) CHRNA7LMNAGRM5KDM4ES1PR1
SCHEMBL14474206 0.89 CYP1A2 (0.43) LMNAMAPTKDM4EALDH1A1CYP3A4
SCHEMBL16185158 0.89 CHRNA7 (0.38) CHRNA7LMNAMAPTGRM5EGFR
SCHEMBL14474690 0.89 CHRNA7 (0.38) CHRNA7LMNAMAPTGRM5EGFR
SCHEMBL16184853 0.86 HSD17B10 (0.47) CHRNA7MAPTGRM5KDM4EALDH1A1
SCHEMBL16185127 0.86 KDM4E (0.37) CHRNA7LMNAMAPTGRM5EGFR
SCHEMBL16185141 0.86 CHRNA7 (0.42) CHRNA7LMNAMAPTGRM5EGFR
SCHEMBL16185143 0.85 S1PR1 (0.46) CHRNA7LMNAMAPTGRM5EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 — — US disclosed
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 — — US disclosed
WO-2013003586-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-01-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE PPP2CA, PPP4C, PPP3CB CHRNA7 349/4885LMNA 4832/4885MAPT 509/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback